April 24, 2026 — At a critical juncture of accelerating global biopharmaceutical innovation and the digital transformation of transaction models, TONACEA, a renowned industrial ecosystem platform in China's biopharmaceutical innovation sector, has officially entered into a strategic cooperation with Bio-Link Capital.

Guided by the principle of "complementary advantages and ecosystem co-construction," the two parties will jointly advance a global-oriented biopharmaceutical innovation collaboration platform. TONACEA will leverage its content influence and high-end professional network cultivated over two decades, while Bio-Link Capital will inject its AI-driven transaction data and global BD (Business Development) capabilities. Together, they are committed to connecting pharmaceutical companies, biotech firms, investment institutions, and research institutes to build a sustainable new paradigm for industrial cooperation.

This cooperation marks a key step in the global ecological layout of both parties. Leveraging TONACEA's profound capabilities in China's industrial integration and full-chain resources, combined with Bio-Link Capital's technological advantages in digitalization of pharmaceutical asset transactions, intelligent valuation, and cross-border BD, the two sides will jointly build an open, collaborative, and scalable biopharmaceutical industrial platform to continuously unleash innovation potential and commercial value.

In accordance with the cooperation agreement, the two parties will carry out in-depth cooperation in three core areas:

1、Joint Development of Brand Events and Think Tank Sharing

The two parties will mutually support conferences and industry events hosted by each other. TONACEA will utilize its strong industry appeal to jointly build a globally influential "Content + Transaction" exchange platform with Bio-Link Capital. They will jointly release reports on industry BD transaction trends and enhance industrial connectivity efficiency and brand value through diversified scenarios such as online live broadcasts and international forums.

2、Resource Interconnection and AI Empowerment

Centering on the entire biopharmaceutical industrial chain, the two parties will integrate key resources such as scientific research innovation, investment and financing, and CRO/CDMO. Bio-Link Capital will open its AI-driven project screening and matching system to provide intelligent valuation and potential buyer prediction for high-quality projects on the TONACEA platform; TONACEA will provide in-depth industry insights and an expert network to jointly build a cross-regional and cross-field ecological circle, accelerating the in-depth integration of Chinese and U.S. industries.

3、Innovative Drug BD Global Expansion and Global Deal Acceleration

Linking global MNCs (Multinational Corporations) and overseas investment institutions, the two parties will build an end-to-end acceleration mechanism from project presentation, business matchmaking, and clinical development to commercialization. Bio-Link Capital will leverage its "Bloomberg Terminal-style" decision support capabilities to help Chinese innovative pharmaceutical companies secure better terms in BD negotiations, improve the global development efficiency of high-potential innovative assets, and achieve a leap from "going global by borrowing ships" to "going global by building ships."

Dr. Zengjiang Cheng, Founder and Chairman of TONACEA, stated: "This cooperation fully embodies our mission of 'Connecting the Global Ecosystem and Empowering Biopharmaceutical Innovation and Growth'. Bio-Link Capital's exploration in the field of transaction digitalization is impressive. Through in-depth cooperation with Bio-Link Capital, we will build a key service platform connecting the Chinese and U.S. markets, continuously create high-quality cross-border cooperation opportunities, and release industrial synergy value."

CEO of Bio-Link Capital KEN stated: "TONACEA is a leading indicator of China's biopharmaceutical innovation, possessing the deepest industry accumulation. Bio-Link Capital is committed to becoming the 'Bloomberg Terminal' of the pharmaceutical industry; we provide not just a trading venue, but deep decision support. This partnership with TONACEA involves embedding our AI algorithms and data capabilities into China's most active innovation ecosystem, helping more Chinese biotechs find a definite path to global expansion amidst the capital winter, and ensuring good assets command good prices."

As a key implementation of the cooperation, Bio-Link Capital will host a dedicated session at the inaugural China Pharmaceutical Innovation Conference (CPIC 2026), focusing on overseas transfer of projects from Chinese enterprises, as well as fields and projects of key interest to overseas enterprises and investment institutions, to build a precise and efficient cross-border matchmaking bridge.

About Bio-Link Capital

Bio-Link Capital is committed to building a world-leading platform for pharmaceutical asset transactions and equity trading. Relying on AI-driven big data analysis and deep industry resources, Bio-Link Capital provides biopharmaceutical companies with one-stop services ranging from BD transaction strategy, intelligent valuation, and cross-border matchmaking to investment and financing consulting, aiming to eliminate information asymmetry and improve the efficiency of global pharmaceutical resource allocation.